Table 2 Ongoing Trials of Amivantamab
From: The development of amivantamab for the treatment of non-small cell lung cancer
Clinical Trial | Study Drugs | Disease | Patients | Phase | Primary Outcome | Status |
|---|---|---|---|---|---|---|
NCT04538664 PAPILLON | amivantamab + carboplatin + pemetrexed vs. carboplatin + pemetrexed | NSCLC | N = 300 | 3 | PFS | Recruiting |
NCT04487080 MARIPOSA | amivantamab + lazertinib vs. osimertinib vs. lazertinib | NSCLC | N = 1074 | 3 | PFS | Active, not recruiting |
NCT04988295 MARIPOSA-2 | amivantamab + lazertinib + platinum chemotherapy | NSCLC | N = 600 | 3 | PFS | Recruiting |
NCT05388669 PALOMA-3 | amivantamab + lazertinib | NSCLC | N = 640 | 3 | Serum concentration | Recruiting |
NCT04965090 | amivantamab + Lazertinib | NSCLC | N = 40 | 2 | CNS ORR | Recruiting |
NCT05074940 | amivantamab | Adenoid cystic carcinoma | N = 18 | 2 | ORR | Recruiting |
NCT05299125 | amivantamab, lazertinib, carboplatin, pemetrexed | NSCLC | N = 49 | 2 | PFS, OS | Not yet recruiting |
NCT05117931 | amivantamab | Esophagogastric cancer | N = 25 | 2 | ORR | Recruiting |
NCT04945733 | amivantamab | Gastric or esophageal cancer | N-79 | 2 | ORR | Recruiting |
NCT05498428 PALOMA-2 | amivantamab | Solid tumors | N = 260 | 2 | ORR, adverse events | Not yet recruiting |
NCT05488314 | amivantamab + capmatinib | NSCLC | N = 147 | 1/2 | Dose limiting toxicity, ORR | Not yet recruiting |
NCT05379595 | amivantamab | Colorectal cancer | N = 225 | 1b/2 | ORR, dose limiting toxicity | Recruiting |
NCT04077463 CHRYSALIS-2 | lazertinib +/- amivantamab | NSCLC | N = 460 | 1/1b | Dose limiting toxicity, ORR | Recruiting |
NCT04085315 | amivantamab + osimertinib | NSCLC | N = 38 | 1/1b | Safety and tolerability | Recruiting |
NCT05395052 | FT536 + amivantamab and other monoclonal antibodies | Solid tumors | N = 322 | 1 | Recommended dose, adverse events | Recruiting |
NCT02609776 CHRYSALIS | amivantamab | NSCLC | N = 780 | 1 | ORR, DOR, dose limiting toxicity | Recruiting |
NCT04606381 PALOMA | amivantamab | Solid tumors | N = 196 | 1 | Serum concentration, dose limiting toxicity | Recruiting |